Access

Brief Communication

Nature Medicine 10, 145 - 147 (2004)
Published online: 25 January 2004 | doi:10.1038/nm988



There is a Corrigendum (June 2004) associated with this Brief Communication.

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G Willett1, Yves Boucher1,10, Emmanuelle di Tomaso1,10, Dan G Duda1,10, Lance L Munn1,10, Ricky T Tong1,10, Daniel C Chung2, Dushyant V Sahani3, Sanjeeva P Kalva3, Sergey V Kozin1, Mari Mino4, Kenneth S Cohen5, David T Scadden5, Alan C Hartford1, Alan J Fischman6, Jeffrey W Clark7, David P Ryan7, Andrew X Zhu7, Lawrence S Blaszkowsky7, Helen X Chen9, Paul C Shellito8, Gregory Y Lauwers4 & Rakesh K Jain1

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Targeted therapies Goldie?Coldman and bevacizumab beyond disease progression

Nature Reviews Clinical Oncology News and Views (01 Jun 2009)

RESEARCH

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts

British Journal of Cancer Original Article

See all 14 matches for Research
$rb.Type.Code